Literature DB >> 3672675

Radical prostatectomy for stage D1 prostate cancer. Prognostic variables and results of treatment.

M Golimbu1, J Provet, S Al-Askari, P Morales.   

Abstract

Surgical extirpation of the primary tumor together with the involved regional nodes has been considered ineffective treatment for locally disseminated prostatic carcinoma. We retrospectively reviewed our experience with 42 patients with Stage D1 disease who underwent radical prostatectomy and bilateral pelvic lymphadenectomy and who had a follow-up of one to thirteen years (mean 5 years). The following variables affecting survival and tumor progression were analyzed: (1) tumor grade and local extent; (2) number of positive lymph nodes, and (3) adjuvant therapy. The overall five- and ten-year survival was 79.5 per cent and 28 per cent compared with the expected survival of an age-matched control group of 88 per cent and 28 per cent, respectively. The degree of tumor differentiation had no effect on prognosis, but local tumor bulk and the number of involved lymph nodes significantly changed the disease progression and survival rate. Patients with low local tumor bulk and one positive node survived as long as the age-matched male population group. Our data suggest that radical prostatectomy may represent a valuable treatment in selected patients with Stage D1 prostate carcinoma.

Entities:  

Mesh:

Year:  1987        PMID: 3672675     DOI: 10.1016/0090-4295(87)90373-6

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  11 in total

Review 1.  [Treatment of locally advanced prostate cancer].

Authors:  M P Wirth; O W Hakenberg; M Fröhner
Journal:  Urologe A       Date:  2005-11       Impact factor: 0.639

2.  Prognostic impact of nodal relapse in definitive prostate-only irradiation.

Authors:  Mauro Loi; Luca Incrocci; Isacco Desideri; Pierluigi Bonomo; Beatrice Detti; Gabriele Simontacchi; Daniela Greto; Emanuela Olmetto; Giulio Francolini; Icro Meattini; Lorenzo Livi
Journal:  Radiol Med       Date:  2018-04-12       Impact factor: 3.469

3.  The importance of pelvic lymph node dissection in men with clinically localized prostate cancer.

Authors:  Mohamad E Allaf; Alan W Partin; H Ballentine Carter
Journal:  Rev Urol       Date:  2006

4.  Does radical prostatectomy in the presence of positive pelvic lymph nodes enhance survival?

Authors:  H A Frazier; J E Robertson; D F Paulson
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

Review 5.  Optimal treatment of locally advanced prostate cancer.

Authors:  Manfred P Wirth; Oliver W Hakenberg; Michael Froehner
Journal:  World J Urol       Date:  2007-02-27       Impact factor: 4.226

Review 6.  Extended lymph node dissection for prostate cancer.

Authors:  Stephan Jeschke; Fiona C Burkhard; Ramesh Thurairaja; Nivedita Dhar; Urs E Studer
Journal:  Curr Urol Rep       Date:  2008-05       Impact factor: 3.092

7.  Number of metastatic lymph nodes as determinant of outcome after salvage radical prostatectomy for radiation-recurrent prostate cancer.

Authors:  G Gugliemetti; R Sukhu; M A Conca Baenas; J Meeks; D D Sjoberg; J A Eastham; P T Scardino; K Touijer
Journal:  Actas Urol Esp       Date:  2016-05-13       Impact factor: 0.994

Review 8.  [Locally advanced prostate carcinoma (T2b-T4 N0) without and with clinical evidence of local progression (Tx N+) with lymphatic metastasis. Is radiotherapy for pelvic lymphatic metastasis indicated or not?].

Authors:  T Wiegel; W Hinkelbein
Journal:  Strahlenther Onkol       Date:  1998-05       Impact factor: 3.621

Review 9.  Role of lymphadenectomy in clinically organ-confined prostate cancer.

Authors:  Nivedita Bhatta Dhar; Fiona C Burkhard; Urs E Studer
Journal:  World J Urol       Date:  2007-02-14       Impact factor: 4.226

Review 10.  Coumarin (1,2-benzopyrone) for the treatment of prostatic carcinoma.

Authors:  J L Mohler; B T Williams; I M Thompson; M E Marshall
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.